Seminars in Oncology
Volume 35, Issue 6 , Pages 569-581, December 2008

Cognitive Effects of Hormonal Therapy in Older Adults

  • Nicholas Mitsiades

      Affiliations

    • Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
  • ,
  • Denise Correa

      Affiliations

    • Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY
  • ,
  • Cary P. Gross

      Affiliations

    • Section of General Internal Medicine, Department of Medicine, Robert Wood Johnson Clinical Scholars Program, Yale University School of Medicine, New Haven, CT
  • ,
  • Arti Hurria

      Affiliations

    • Cancer and Aging Research Program, City of Hope, Duarte, CA
  • ,
  • Susan F. Slovin

      Affiliations

    • Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
    • Corresponding Author InformationAddress correspondence to Susan F. Slovin, MD, PhD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065

There is ample preclinical evidence that gonadal steroids (estrogens and androgens) play an important role in central nervous system development and function. The abrupt decline of estrogen levels in women after menopause, and the slower, subtler decline in total and bioavailable testosterone serum levels that occurs in aging men (“andropause,” “male menopause,” partial androgen deficiency in ageing males [PADAM]), have been implicated in the pathogenesis of cognitive dysfunction prevalent in elderly adults. However, the current clinical evidence supporting hormonal replacement as a neuroprotective therapy is at best inconclusive. Anti-estrogen and anti-androgen hormonal therapies are used in the treatment of breast and prostate carcinomas, respectively. Although generally considered less toxic than conventional cytotoxic chemotherapy, these hormonal manipulations have side effects that are not trivial. This review will summarize the available evidence regarding the impact of these hormonal therapies on cognitive function in older adults. Additional clinical research in this field is needed to confirm the existence and severity of such a possible cognitive impact, which may then need to be considered prior to initiating hormonal therapies in the elderly, as many patients may be in the prodromal phase or early stages of a neurodegenerative disorder, such as Alzheimer's disease, and this information may influence treatment decision-making and subsequent management.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(08)00185-1

doi:10.1053/j.seminoncol.2008.08.002

Seminars in Oncology
Volume 35, Issue 6 , Pages 569-581, December 2008